Nanobodies – A potent alternative

Introduction Biologic drugs are increasingly becoming important as therapeutics for treatment of various diseases, including cancer, infectious and inflammatory diseases. Classical antibody scaffolds and structures are being challenged by smaller but equally potent molecules which have several benefits over classical immunoglobulins. Camelid antibodies have been shown to lack the light chain only carrying effector function… Continue reading Nanobodies – A potent alternative

LIBRA-seq: accelerating antibody discovery

Schematic view of new version of LIBRA-seq with ligand blocking4

With the increased throughput of single cell platforms and sequencing of immune repertoires, new challenges arise and the ability to map individual antibodies to antigens is becoming increasingly important.  What is LIBRA-seq? Mapping B cell receptor-antigen interaction at single cell level  Dr. Georgiev’s group at the Vanderbilt University has developed a high-throughput, highly-multiplexed sequencing-based technique… Continue reading LIBRA-seq: accelerating antibody discovery

NGS, Sanger & PacBio sequencing in Antibody Drug Discovery

Biologics are becoming the drugs of choice when targeting cancers, infectious diseases etc. Monoclonal antibodies have taken up 6 out of 10 of the top selling drugs in the latter years and biologic drugs are expected to keep being some of the most efficient and potent drugs available.  To find good drug candidates new sequencing… Continue reading NGS, Sanger & PacBio sequencing in Antibody Drug Discovery

Non-antibody scaffolds as therapeutics.

PipeBio supports alternative scaffolds like affibodies, bi-cyclic peptides and knottins, as well as more conventional sequences like VHH, IgG, scFv.

non-antibody scaffolds from ERR3474167.fastq downloaded from the European Nucleotide Archive. These non-antibody scaffolds can make great therapeutics due to their small size although there can be tradeoffs.